Showing results (161-170 of 651) with videos related to
Sort By:
Pageof 66
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 25, 2015
¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy RegimenDavid Groheux, Lucie Biard, Sylvie Giacchetti, et al.Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
Long-term outcome of neuro-Behçet's diseaseNicolas Noel, Remy Bernard, Bertrand Wechsler, et al.Journal of the American Heart Association|December 21, 2018
Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 PatientsAlexandre Le Joncour, Simon Soudet, Axelle Dupont, et al.Journal of Critical Care|April 1, 2017
Gastrointestinal emergencies in critically ill cancer patientsDelphine Lebon, Lucie Biard, Sophie Buyse, et al.BMJ (Clinical Research Ed.)|August 18, 2017
Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks' gestation in France in 2011: EPIPAGE-2 cohort studyVéronique Pierrat, Laetitia Marchand-Martin, Catherine Arnaud, et al.Journal of Biopharmaceutical Statistics|August 20, 2010
Retrospective robustness of the continual reassessment methodJohn O'Quigley, Sarah ZoharStatistics in Medicine|September 14, 2006
Optimal designs for estimating the most successful doseSarah Zohar, John O'QuigleyContemporary Clinical Trials|July 8, 2009
Sensitivity of dose-finding studies to observation errorsSarah Zohar, John O'QuigleyPharmaceutical Statistics|November 4, 2006
Identifying the most successful dose (MSD) in dose-finding studies in cancerSarah Zohar, John O'QuigleyOncotarget|April 18, 2018
18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patientsPatricia de Cremoux, Lucie Biard, Brigitte Poirot, et al.Pageof 66